Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
04 Março 2025 - 11:15AM
Leiden, the Netherlands, March 4,
2025: Pharming Group N.V. (“Pharming” or “the
Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today
that the Extraordinary General Meeting of Shareholders (EGM) has
adopted all proposals on the EGM agenda.
Shareholders approved the appointment of Mr.
Fabrice Chouraqui as Executive Director and Chief Executive Officer
for a term of four years.
As a result, Mr. Chouraqui succeeds Mr. Sijmen
de Vries with immediate effect. To ensure a smooth hand-over of
tasks and responsibilities, Mr. de Vries will remain a strategic
advisor to the new CEO until December 31, 2025.
In addition, shareholders also approved the
proposal to approve certain components of the remuneration package
of Mr. Chouraqui in his capacity as Executive Director and Chief
Executive Officer.
A recording of the webcast, presentation slides
from today’s EGM, and more details regarding both agenda items are
available on the Pharming website in the Investor Relations
section.
Dr. Richard Peters, Chairman of the
Board of Directors, commented:“On behalf of the entire
Board, we welcome Fabrice Chouraqui as our new Executive Director
and Chief Executive Officer and we look forward to working with him
to deliver on Pharming’s objectives and to further strengthen the
company’s position in the rare disease market. We would also like
to thank our outgoing Chief Executive Officer, Sijmen de Vries, for
his significant accomplishments and leadership over the past 16
years and for remaining as strategic advisor through year end.”
About Pharming Group
N.V. Pharming Group N.V. (EURONEXT Amsterdam:
PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated
to transforming the lives of patients with rare, debilitating, and
life-threatening diseases. Pharming is commercializing and
developing an innovative portfolio of protein replacement therapies
and precision medicines, including small molecules and biologics.
Pharming is headquartered in Leiden, the Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and
find us on LinkedIn.
Inside InformationThis press
release relates to the disclosure of information that qualifies, or
may have qualified, as inside information within the meaning of
Article 7(1) of the EU Market Abuse Regulation.
For further public information,
contact:Pharming Group, Leiden, the NetherlandsMichael
Levitan, VP Investor Relations & Corporate CommunicationsT: +1
(908) 705 1696E: investor@pharming.com
FTI Consulting, London, UKSimon Conway/Alex
Shaw/Amy ByrneT: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam,
the NetherlandsLeon MelensT: +31 6 53 81 64 27E:
pharming@lifespring.nl
- Pharming EGM 2025 PR_EN_04MAR25
Pharming Group NV (EU:PHARM)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Pharming Group NV (EU:PHARM)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
